SCHEMBL5596624

SCHEMBL5596624

C=Cc1ncc2c3c(cccc13)N(C1CCCN(C(=O)OC(C)(C)C)C1)CC2

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.41
SCN9A Q15858 1/20 0.39
FPR2 P25090 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
BCHE P06276 2/20 0.38
HTR6 P50406 2/20 0.38
HPGDS O60760 1/20 0.38
BRD4 O60885 1/20 0.38
USP30 Q70CQ3 3/20 0.36
TNF P01375 2/20 0.36
LITAF Q99732 2/20 0.36
KDM1A O60341 1/20 0.36
HCAR1 Q9BXC0 1/20 0.36
ACKR3 P25106 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5596618 0.90 BRD4 (0.42) SCN9AFPR2PRMT5WDR77BCHE
SCHEMBL5597044 0.87 SCN9A (0.42) SCN9AFPR2BCHEHTR6HPGDS
SCHEMBL5596748 0.87 HTR6 (0.41) SCN9AFPR2PRMT5WDR77BCHE
SCHEMBL5596364 0.86 TNF (0.40) FGFR4SCN9AFPR2PRMT5WDR77
SCHEMBL5596881 0.86 FPR2 (0.42) FGFR4SCN9AFPR2PRMT5WDR77
SCHEMBL5596791 0.86 HPGDS (0.40) SCN9AFPR2PRMT5WDR77BCHE
SCHEMBL5596880 0.83 USP30 (0.43) SCN9AFPR2BCHEHTR6HPGDS
SCHEMBL5596756 0.82 HTR6 (0.40) SCN9AFPR2PRMT5WDR77BCHE
SCHEMBL5596780 0.82 TNF (0.43) SCN9AUSP30TNFLITAF
SCHEMBL5596980 0.81 USP30 (0.42) SCN9AFPR2PRMT5WDR77BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1829876-A1 NITROGENEOUS TRICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2007-09-05 EP disclosed
US-20060247266-A1 Nitrogen-containing tricyclic compounds ASAHI KASEI PHARMA CORPORATION (JP) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247266-A1 Nitrogen-containing tricyclic compounds MYO1B, CHRM1, MYL12A FGFR4 4030/4885SCN9A 1303/4885FPR2 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.